ArticleLower urinary tract symptoms2026
Safety and Efficacy of Rezūm Water Vapor Energy Therapy for Benign Prostatic Hyperplasia With Continued Antithrombotic Therapy: A Comparative Study.
Article in Lower urinary tract symptoms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEvidence regarding the safety of water vapor energy (WAVE) therapy in patients continuing antithrombotic (AT) agents remains limited. This study compared the safety and efficacy of WAVE therapy between patients receiving AT therapy and those not receiving such therapy.
methodsThis retrospective comparative study included 103 consecutive patients who underwent WAVE therapy at a single institution between February 2023 and October 2024. Patients were divided into an AT group (n = 36) and a non-AT group (n = 67). All AT agents continued throughout the perioperative period. Postoperative complications were graded according to the Clavien-Dindo classification. Changes in symptom scores and uroflowmetry parameters were evaluated at baseline and at 3 and 6 months after treatment in patients without a preoperative indwelling catheter.
resultsBaseline characteristics were generally similar between the two groups, although patients in the AT group were significantly older than those in the non-AT group. Early postoperative bleeding events were comparable (11.1% in the AT group vs. 4.5% in the non-AT group, p = 0.24), and no grade ≥ 3 complications occurred in either group. Late complications occurred only in the non-AT group (6.0%). In the overall cohort, the median IPSS total score decreased from 18.5 (interquartile range: 12.0-25.0) at baseline to 9.0 (3.0-12.8) and 6.0 (3.0-10.8) at 3 and 6 months, respectively. Post-void residual volume decreased from 111 (interquartile range: 52.8-180) mL at baseline to 55.5 (27.3-102) and 50.5 (24.5-92.3) mL. These improvements were comparable between groups.
conclusionsWAVE therapy appeared feasible in patients who continued AT therapy, with acceptable short-term safety and symptomatic improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.